logo
#

Latest news with #VitrolifeGroup

Announces Syndicated Investment Round, Led by Vitrolife AB (publ)
Announces Syndicated Investment Round, Led by Vitrolife AB (publ)

Business Wire

time09-05-2025

  • Business
  • Business Wire

Announces Syndicated Investment Round, Led by Vitrolife AB (publ)

NATICK, Mass.--(BUSINESS WIRE)-- AutoIVF Inc., a pioneering fertility care company, has closed an equity investment round, led by Vitrolife Group, with participation from new investors including Alpha Edison and IVF industry stalwarts. AutoIVF's flagship product, OvaReady, is a groundbreaking automated system that simplifies and enhances egg retrieval and preparation in the current IVF process and supports decentralizing the egg retrieval process outside traditional IVF laboratory settings. According to the World Health Organization (WHO), one in six people globally will experience infertility at some point in their lives. This underscores the urgent need for accessible, high-quality fertility care worldwide. Led by CEO Ravi Kapur Ph.D., FAIMBE, AutoIVF's founding and leadership team brings more than 200 years of combined experience in IVF, microfluidics, and reproductive health, driving its mission to democratize fertility care, expand global access, and reimagine the future of assisted reproductive technologies. 'The National Institutes of Health's ongoing support through their Small Business Innovation Research Awards has validated the strength of our technology and our rigorous clinical approach. This foundation has enabled us to demonstrate the real-world impact of OvaReady. With this new investment and partnership, we're excited to accelerate our path to market and explore collaborations that can expand access, scale innovation, and create lasting value across the reproductive health ecosystem,' said Ravi Kapur, CEO of AutoIVF. ''This investment and partnership mark another step in our corporate strategy to build an end-to-end platform that connects products and services across the entire IVF workflow. By continuing to automate the IVF process we will enable safe, efficient and effective fertility care,' says Bronwyn Brophy O'Connor, CEO of the Vitrolife Group. Erin Schardt, SVP and GM North America at Vitrolife Group, will join AutoIVF's Board of Directors. About AutoIVF AutoIVF is pioneering a new era in fertility care by making in vitro fertilization (IVF) more accessible, affordable, and efficient. Our flagship technology, OvaReady, is a groundbreaking automated system that simplifies and enhances egg collection and preparation for the current IVF process, while enabling high-quality fertility services to be delivered outside traditional IVF labs. Backed by a team with over 200 years of combined expertise in IVF, women's health, microfluidics, and cryobiology, we are committed to transforming the delivery of fertility treatment. The Company has raised over $16 million in public and private funding, including major National Institute of Health SBIR awards. About Vitrolife Group Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.

The Vitrolife Group appoints Pär Ihrskog as the new Chief Financial Officer
The Vitrolife Group appoints Pär Ihrskog as the new Chief Financial Officer

Yahoo

time10-04-2025

  • Business
  • Yahoo

The Vitrolife Group appoints Pär Ihrskog as the new Chief Financial Officer

GOTHENBURG, Sweden, April 10, 2025 /PRNewswire/ -- Pär Ihrskog has been appointed CFO of the Vitrolife Group effective 10 October 2025. Pär currently serves as CFO at Bufab Group and brings a wealth of experience to the company, having also served as Group CFO/CIO at Embellence Group. He spent the majority of his career working in finance roles, of increasing seniority in SKF, also living and working in several countries, including the U.S. and China. Pär holds a master's degree in business administration. "We are delighted to welcome Pär Ihrskog to the Vitrolife Group as CFO. His extensive financial expertise, combined with a proven track record of leadership in listed companies, brings valuable strategic and operational insight that will support the company in driving sustainable profitable growth," says Bronwyn Brophy O'Connor, CEO. Helena Wennerström will remain as acting CFO until Pär takes office. Gothenburg, 10 April 2025VITROLIFE AB (publ)Bronwyn Brophy O'Connor, CEO The information was submitted for publication, through the agency of the contact persons set out above, at 10-04-2025 12:00 CET. Contact:Amelie Wilson, Investor Relations, awilson@ This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails. This information was brought to you by Cision The following files are available for download: The Vitrolife Group appoints Pär Ihrskog as the new Chief Financial Officer View original content: SOURCE Vitrolife AB (publ)

Vitrolife Group Annual and Sustainability Report 2024
Vitrolife Group Annual and Sustainability Report 2024

Yahoo

time27-03-2025

  • Business
  • Yahoo

Vitrolife Group Annual and Sustainability Report 2024

GOTHENBURG, Sweden, March 27, 2025 /PRNewswire/ -- Vitrolife Group has today published its Annual and Sustainability Report for 2024. The Annual and Sustainability Report is now available digitally in English and Swedish at The Annual Report in accordance with European Single Electronic Format (ESEF) is available in Swedish. Vitrolife Group has chosen not to print or distribute a hard copy of the Annual Report. Those who are unable to access the Annual Report digitally can request a print-out of the Annual Report by contacting Vitrolife Group at investors@ or call +46 (0) 31 721 80 00. Gothenburg, SwedenMarch 27, 2025VITROLIFE AB (publ) This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 27-03-2025 09:00 CET. Contact:Amelie Wilson, Investor Relations, awilson@ This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails. This information was brought to you by Cision The following files are available for download: Vitrolife Group Annual and Sustainability Report 2024 View original content: SOURCE Vitrolife AB (publ)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store